This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

ZEPATIER® (elbasvir/grazoprevir)

DDIs and dosing simplicity

tbc

ZEPATIER can be used with the following drugs without clinically significant interactions or dose adjustments2,3

Other categories without clinically significant interactions or dose adjustments include: antiarrhythmics (digoxin), antidepressants*, beta blockers, gastric acid suppressants (H2-receptor antagonist (famotidine), Proton Pump Inhibitor (pantoprazole), antacids), HBV and HIV NRTIs, HIV NNRTIs (rilpivirine), HIV integrase inhibitors (raltegravir and dolutegravir), HCV antivirals (sofosbuvir and ribavirin), immunosuppressants (prednisone, mycophenolate mofetil), phosphate binders (calcium acetate, sevelamer carbonate) and statins (pitavastatin, pravastatin).

Please consult the ZEPATIER SmPC before prescribing.2

*Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required3

Other statins (HMG-CoA reductase inhibitors) - use low dose when concomitantly given with ZEPATIER2

Glucose levels of diabetic patients initiating DAA therapy should be closely monitored, particularly within the first 3 months, and their diabetic medication modified when necessary

Contraindications
Dosing simplicity2

Cure defined as Cure of HCV infection = Sustained Virologic Response (SVR), the primary endpoint in all studies, was defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) less than the Lower Limit of Quantification (LLOQ) (≤15 IU/ml) at 12 weeks after the cessation of treatment.4

References

  1. Höner zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561–567.
  2. ZEPATIER Summary of Product Characteristics.
  3. Liverpool Drug Interactions Group, University of Liverpool. https://www.hepdruginteractions.org/view_all_interactions/582987.
  4. European Association for the Study of Liver. J Hepatol 2018;69;461-511.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-ZEP-00146 | Date of Preparation: November 2021